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Introduction:  Infantile  hemangioma  (IH)  is  one  of  the  most  common  childhood  tumors.  There
are various  medical  or  surgical  therapeutic  options,  all  with  suboptimal  results.  Recently,  the
successful use  of  propranolol  for  involution  of  IH  was  described.  We  report  the  results  of  a
single-center  experience  with  this  therapeutic  option.
Objective:  To  prospectively  assess  the  efﬁcacy  and  safety  of  propranolol  in  children  with  infan-
tile hemangioma.
Methods:  We  performed  a  prospective  analysis  of  clinical  data  of  all  patients  with  IH  referred
to a  pediatric  cardiology  center  for  baseline  cardiovascular  assessment  prior  to  propranolol
therapy. Propranolol  was  given  at  a  starting  dose  of  1  mg/kg/day  and  titrated  to  a  target  dose
of 2--3  mg/kg/day  according  to  clinical  response.  Efﬁcacy  was  assessed  through  a  photograph-
based severity  scoring  scale.  Safety  was  assessed  by  collecting  data  regarding  signiﬁcant  side
effects.
Results: Starting  in  2010,  30  patients  (15  female)  were  referred  for  propranolol  treatment
of IH,  at  a  median  age  of  six  months  (1--63  months).  The  mean  target  propranolol  dose  was
2.8 mg/kg/day,  with  a  mean  duration  of  therapy  of  12  months.  All  patients  experienced  signif-
icant reduction  of  IH  size  and  volume.  There  were  no  side  effects.
Conclusions:  In  our  experience  propranolol  appears  to  be  a  useful  and  safe  treatment  option  for
severe or  complicated  IH,  achieving  a  rapid  and  signiﬁcant  reduction  in  their  size.  No  adverse
effects were  observed,  although  until  larger  clinical  trials  are  completed,  potential
adverse events  should  be  borne  in  mind  and  consultation  with  local  specialists  is  recommended
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O  papel  do  propranolol  no  tratamento  dos  hemangiomas  em  idade  pediátrica
Resumo
Introduc¸ão:  Os  hemangiomas  são  a  lesão  tumoral  cutânea  mais  frequente  em  idade  pediátrica.
Até ao  momento  todas  as  opc¸ões  terapêuticas  (tanto  médicas  como  cirúrgicas)  têm  resulta-
dos sub-ótimos.  Recentemente,  foi  descrita  a  utilizac¸ão  de  propranolol  para  tratamento  dos
hemangiomas.  Relatamos  os  resultados  da  nossa  experiência  com  esta  opc¸ão terapêutica.
Objetivo:  Avaliac¸ão  prospetiva  da  eﬁcácia  e  seguranc¸a de  propranolol  em  crianc¸as  com  heman-
gioma infantil.
Métodos:  Avaliac¸ão  prospetiva  de  todos  os  doentes  com  hemangioma  referenciados  para
avaliac¸ão cardiovascular  prévia  ao  início  de  terapêutica  com  propranolol.  O  propranolol  foi
administrado  numa  dose  inicial  de  1  mg/kg/dia  e  titulada  para  uma  dose  alvo  de  2--3  mg/kg/dia,
de acordo  com  a  resposta  clínica.  A  eﬁcácia  foi  avaliada  através  de  uma  escala  fotográﬁca.
A seguranc¸a  foi  avaliada  através  da  recolha  de  dados  sobre  os  efeitos  secundários  signiﬁcativos.
Resultados:  Desde  2010,  30  crianc¸as  (15  do  sexo  feminino)  com  hemangiomas  foram  referenci-
ados para  avaliac¸ão  cardiovascular  prévia  ao  início  de  terapêutica  beta-bloqueante,  com  uma
idade média  de  6  meses  (1-63  meses).  A  dose  alvo  média  atingida  foi  de  2,8  mg  /  kg  /  dia,
com uma  durac¸ão  média  de  tratamento  de  12  meses.  Em  todos  os  doentes  se  veriﬁcou  uma
reduc¸ão signiﬁcativa  das  dimensões  e  volume  dos  hemangiomas.  Não  foram  observados  efeitos
colaterais.
Conclusões:  Na  nossa  experiência,  o  propranolol  é  uma  opc¸ão  eﬁcaz  e  segura  para  o  tratamento
de hemangiomas  extensos  ou  complicados,  obtendo-se  uma  reduc¸ão  rápida  e  signiﬁcativa  das
suas dimensões.  Não  foram  observados  efeitos  adversos  contudo,  recomenda-se  a  avaliac¸ão
cardiovascular  sistemática,  prévia  ao  início  de  terapêutica  com  propranolol.
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nfantile  hemangiomas  are  the  most  common  benign  vas-
ular  tumors  in  infancy,  affecting  5--10%  of  the  population.
emales  are  affected  more  often  than  males,  with  a  ratio
f  3:1.1 Typically  they  present  shortly  after  birth,  undergo
 period  of  rapid  proliferation,  and  then  slowly  involute
ver  many  years.2,3 Although  most  are  small  cutaneous  vas-
ular  malformations  of  the  face,4 they  can  also  be  large,
isﬁguring  lesions  with  serious  complications.  Infants  with
arge  hemangiomas,  especially  those  with  a  segmental  dis-
ribution  or  hemangiomatosis,  are  at  particular  risk  for
xtracutaneous  complications.  They  may  also  be  associ-
ted  with  other  congenital  malformations,  such  as  PHACE,5
ELVIS4 or  SACRAL  syndrome.6,7
In  most  cases  only  parental  education  and  reassurance
re  required.  Although  85--90%  of  all  infantile  hemangiomas
ventually  undergo  spontaneous  involution,  a  minority  can
till  cause  disﬁgurement  and  serious  complications,  depend-
ng  on  their  location  (obstruction  of  airways  and  vision),
ize,  and  speed  of  regression,  which  can  be  associated
ith  painful  ulcerations  and  hemorrhage  or  even  high-
utput  heart  failure.4,8,9 Hemangiomas  with  the  potential  to
hreaten  a  child’s  life  or  vital  functions  and  those  that  ulcer-
te  or  cause  substantial  disﬁgurement  warrant  treatment,10hich  may  be  medical  or  surgical,  or  a  combination  of
oth.11
At  present  there  is  no  gold  standard  medical  treatment.




duccess  and  signiﬁcant  adverse  effects  that  limit  their
se.12--16 Since  Léauté-Labrèze’s  accidental  observation17
f  the  anti-proliferative  effect  of  propranolol  on  infan-
ile  hemangiomas,  propranolol  has  become  increasingly
opular18,19 as  a  successful  therapeutic  option,  with  fewer
ide  effects  than  other  treatments.
We  present  a  single-center  study  describing  the  efﬁcacy
nd  safety  of  propranolol  in  children  with  infantile  heman-
iomas.
ethods
nclusion  and  exclusion  criteria
ll  patients  were  referred  by  their  pediatric  dermatologist
r  pediatric  surgeon  to  a  pediatric  cardiology  department
or  baseline  cardiovascular  assessment  prior  to  propranolol
herapy,  and  cardiovascular  assessment  during  therapy.
Patients  with  infantile  hemangiomas  were  considered
or  propranolol  treatment  if  they  met  the  following  cri-
eria:  eyelid  involvement  with  risk  of  ocular  occlusion  or
ompression;  airway  obstruction;  or  large  hemangioma  with
igniﬁcant  disﬁgurement  or  ulceration.  Patients  previously
reated  with  other  therapeutic  modalities  were  also  con-
idered  candidates  for  inclusion  if  the  previous  treatment
ad  failed.  Exclusion  criteria  included  cardiac  anomalies,
entral  nervous  system  vascular  anomalies  as  in  PHACE  syn-
rome,  hypoglycemia,  asthma  or  bronchospasm.  While  the
a  291
Table  1  Summary  of  patient  characteristics.
n=30
Female:male  ratio  1:1
Type of  hemangioma
Superﬁcial  25
Deep 5
Distribution  of  hemangioma
Head  8
Periocular/eyelid  involvement  9
Peribuccual  involvement  4
Thoracic  involvement  5
Limb involvement  4
Baseline  assessment  (blood  pressure,  fasting  blood
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study  focused  on  infants,  patients  over  one  year  of  age
were  enrolled  if  their  hemangiomas  showed  signs  of  contin-
ued  proliferation  or  had  shown  no  signs  of  resolution  since
infancy.
Treatment  protocol
All  patients  underwent  full  cardiac  examination  before
treatment,  which  included  clinical  examination,  heart  rate
and  blood  pressure  measurements,  electrocardiogram,  and
echocardiogram.  A  baseline  ﬁngerstick  blood  glucose  level
was  obtained.  Further  monitoring  during  the  study  included
a  weekly  re-evaluation  while  the  dose  was  being  titrated
to  its  maximum  target  dose,  at  weeks  1--4.  Parents  were
instructed  to  look  for  signs  of  lethargy,  poor  feeding  or
wheezing.  After  the  ﬁrst  month,  monthly  follow-up  visits
were  scheduled  until  the  end  of  the  treatment  for  sever-
ity  scoring  of  the  hemangiomas,  physical  assessment  and
monitoring  for  adverse  effects.
Dosage  and  duration
Propranolol  was  given  at  a  starting  dose  of  1  mg/kg/day,  in
two  or  three  divided  doses,  and  titrated  to  a  target  dose  of
2--3  mg/kg  per  day  according  to  clinical  response.
Severity  scoring  system
A  photograph-based  severity  scoring  scale  was  used.  Frontal
and  lateral  pictures  of  every  patient  were  taken  before
treatment  and  at  every  follow-up  visit.
Results
Starting  in  2010  thirty  patients  were  included  in  this  study,
of  whom  15  (50%)  were  female;  none  were  born  prema-
turely.  Superﬁcial  hemangioma  was  the  predominant  type,
observed  in  25  (83%)  patients,  whereas  in  three  (10%)
the  hemangiomas  had  a  segmental  distribution  (Table  1).
The  most  frequent  location  was  facial-cervical  (70%).  Pro-
pranolol  was  started  at  a  median  age  of  six  months  (1--
63  months);  the  oldest  patient  was  ﬁve  years  old.  The  mean
target  propranolol  dose  was  2.8  mg/kg/day  (range  2.5--
3.2  mg/kg/day).  The  mean  duration  of  therapy  was  12
months.  All  patients  experienced  immediate  color  changes
and  effects  on  the  rate  of  hemangioma  growth;  in  all
patients  a  reduction  of  its  size  and  volume  was  seen
(Figures  1--3).  No  adverse  effects  were  identiﬁed  or  reported
by  the  patients  or  their  parents.  Propranolol  was  discon-
tinued  in  ﬁve  patients  when  the  residual  lesions  ceased  to
respond  to  therapy;  one  had  a  slight  relapse  but  it  was  not
necessary  to  re-start  propranolol.
In  this  group  of  patients  propranolol  therapy  had  simi-
lar  effectiveness  regardless  of  age  at  initiation  of  treatment
(before  or  after  six  months  of  age).  It  was  equally  effective
in  hemangiomas  considered  to  be  beyond  the  prolifera-
tive  phase.  Also,  segmental  and  nonsegmental,  superﬁcial,
mixed,  and  deep  infantile  hemangiomas  showed  a  similar







n  our  experience  propranolol  appears  to  be  a  useful  treat-
ent  for  severe  or  complicated  infantile  hemangiomas,
chieving  a  rapid  and  signiﬁcant  reduction  in  size.  This
eduction  was  mainly  achieved  during  the  ﬁrst  20  weeks  of
reatment,  and  further  treatment  induced  a less  dramatic
herapeutic  effect.  In  this  series  of  patients  propranolol
as  equally  effective  in  both  segmental  and  nonsegmental
nfantile  hemangiomas  and  in  those  beyond  the  proliferative
hase.
Infantile  hemangiomas  have  a  predictable  natural
istory.4,20 The  majority  are  not  present  at  birth.  A  hallmark
f  infantile  hemangioma  is  its  dramatic  growth  after  birth,
y  diffuse  proliferation  of  immature  endothelial  cells,  fol-
owed  by  spontaneous  regression.  The  majority  of  children
ith  infantile  hemangiomas  require  no  treatment  as  the
esions  regress  over  time  and  produce  no  long-term  scarring;
egression  is  complete  in  50%  of  ﬁve-year-old  patients  and
0%  of  nine-year-olds.16 In  approximately  10%  of  cases  there
an  be  serious  or  life-threatening  hemangiomas,  requiring
reatment.10
Current  treatment  options  for  complicated  heman-
iomas  include  various  medical  or  surgical  modalities.
ntil  recently,  the  mainstay  of  treatment  for  infantile
emangiomas  was  corticosteroids  in  various  forms,  includ-
ng  topical,  intralesional,  and  oral  formulations,  the  most
ommon  being  oral  prednisolone.12 Only  in  complicated  or
efractory  hemangioma  cases  have  other  treatment  modal-
ties  been  considered,  such  as  chemotherapeutic  agents
vincristine,  interferon-alpha),  laser  therapy,  surgery  or
 combination  of  these,  and,  most  recently,  propranolol.
ach  treatment  option  has  limited  therapeutic  beneﬁt,
ith  its  own  side  effects  and  risks.  However,  in  the  past
hree  years  there  have  been  more  than  120  reports  of
he  efﬁcacy  of  oral  beta-blockers,  usually  propranolol,  as
292  S.  Laranjo  et  al.
Figure  1  A  four-month-old  girl  who  presented  with  a  large  hemangioma  on  the  left  upper  eyelid,  showing  complete  involution  of
the lesions  after  ﬁve  months  of  oral  propranolol.  M:  months.
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high and  scrotum  after  eight  months  of  therapy.  M:  months.
 highly  effective  therapeutic  option  for  infantile  heman-
ioma  and  its  complications.18,21--23 Furthermore,  it  has
een  demonstrated  that  propranolol  therapy  is  superior  to
ral  corticosteroid  treatment,  the  former  standard  ther-
py  for  infantile  hemangioma,  and  should  be  considered
he  ﬁrst-line  agent  given  its  safety  and  efﬁcacy.24 Possi-
le  explanations  for  the  therapeutic  effect  of  propranolol
n  hemangiomas  include  vasoconstriction  by  decreasing  the




igure  3  A  ten-month-old  boy  with  hemangioma  on  the  right  pate
f therapy.  M:  months.n  the  left  thigh,  showing  complete  involution  of  the  lesion  on
hange  in  color,  associated  with  palpable  tissue  softening.
ther  suggestions  are  down-regulation  of  proangiogenic  sig-
als  such  as  VEGF,  bFGF,  MMP-9  and  HBMEC,  and  induction
f  apoptosis  in  proliferating  capillary  endothelial  cells.25,26
 large  international  randomized  clinical  trial  is  under-
ay,  but  many  are  already  advocating  its  use  as  a  ﬁrst-line
reatment  for  infantile  hemangiomas,  in  terms  of  both
afety  and  efﬁcacy.21,27 Its  effects  were  ﬁrst  discovered
y  chance  by  Léauté-Labrèze  et  al.  in  2008.17 Subsequent
lla  and  upper  right  leg,  showing  a  fair  response  after  18  months
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- risk of ulceration
- risk of organ dysfunction

















- Start with 1 mg/kg/day







- Clinical assessment every three months
- Photograph lesions at each assessment 
- If complete regression or plateau:
start progressive weaning  – reduce dosage by 1 mg/kg/day weekly
- If rebound:
return to previous dosage
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reports  have  emphasized  propranolol’s  role  not  only  in  halt-
ing  hemangioma  growth  but  also  in  diminishing  their  size.21
Most  groups  have  used  a  maximum  target  dose  of  1--3
mg/kg/day.9,11,17,18,21,22,28--37 However,  there  are  no  estab-
lished  consistent  protocols,  particularly  regarding  the  timing
of  treatment  tapering  and  discontinuation.9,11,17--19,21,22,28--37
There  is  also  no  consensus  regarding  the  relapse  rate  after
discontinuation,  with  some  studies  showing  no  relapses,30--32
while  others  report  minor  recurrences.17,18,36 In  our  short
series  only  one  of  the  patients  in  whom  propranolol  was
tapered  showed  a  slight,  non-signiﬁcant,  relapse,  with  no
need  to  re-start  treatment.
Until  recently,  the  most  common  approach  for  patients
with  infantile  hemangiomas  in  the  post-proliferative  phase
was  ‘‘active  non-intervention’’.38 In  our  series,  propra-
nolol  improved  esthetics  in  all  patients,  giving  scope  for




s work-up  and  treatment  protocol.
ecessary.  These  ﬁndings  are  consistent  with  those  reported
y  Zvulunov  et  al.,39 Schupp  et  al.36 and  Celik  et  al.,21
ho  reported  the  results  of  propranolol  therapy  for  heman-
iomas  beyond  the  proliferative  phase,  and  imply  that  oral
ropranolol  therapy  may  be  warranted  in  children  with
ate  residual  infantile  hemangiomas,  prior  to  any  surgical
ntervention.21 Still,  the  most  impressive  responses  occurred
n  the  youngest  patients,  a  ﬁnding  that  is  consistent  with
he  natural  history  of  hemangioma,  in  which  80%  of  its  size
s  reached  by  six  months  of  age,  and  justiﬁes  referring  such
ases  earlier  for  optimal  therapeutic  response.
The  appropriate  monitoring  protocol  for  assessment  of
dverse  effects  in  infants  with  infantile  hemangiomas,
efore  and  during  propranolol  treatment,  has  not  been
stablished.18,19 The  potential  side  effects  of  beta-blockers,
hich  are  well  known  and  include  bradycardia,  hypoten-
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ropranolol  is  also  contraindicated  in  patients  with
sthma,  and  it  is  not  recommended  during  episodes  of
ronchiolitis.18,45 Notwithstanding,  propranolol  appears  to
e  a  safe  drug  when  correctly  administered.  No  adverse
ffects  were  observed  in  our  series;  none  of  our  patients
ad  symptoms  of  hypoglycemia  or  hypotension.  However,
ntil  larger  clinical  trials  are  completed,  potential  adverse
vents  should  be  borne  in  mind  and  consultation  with  local
pecialists  such  as  pediatric  cardiologists  is  recommended
rior  to  initiating  treatment.  Patients  with  PHACE  syndrome
nd  severe  cerebrovascular  disease  are,  at  least  in  theory,  at
isk  for  brain  ischemia  even  with  the  relatively  mild  hypoten-
ion  induced  by  beta-blockers.19 The  risks  and  beneﬁts  in  this
ubset  of  patients  must  be  weighed  carefully.  Figure  4  sum-
arizes  our  treatment  algorithm  based  on  our  experience.
In  conclusion,  a  better  understanding  of  the  mechanisms
f  propranolol-induced  regression  of  infantile  hemangiomas
ill  provide  opportunities  to  design  even  more  success-
ul  therapies.  Meanwhile,  propranolol  appears  to  be  a
niquely  effective  and  safe  therapy  for  infantile  heman-
iomas,  including  in  the  post-proliferative  phase,  and  should
e  considered  the  ﬁrst-line  therapy  in  this  setting.
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